Article 1
The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.
Commission Implementing Regulation (EU) 2022/1480 of 7 September 2022 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 2-phenylphenol (including its salts such as the sodium salt), 8-hydroxyquinoline, amidosulfuron, bensulfuron, bifenox, chlormequat, chlorotoluron, clofentezine, clomazone, daminozide, deltamethrin, dicamba, difenoconazole, diflufenican, dimethachlor, esfenvalerate, etofenprox, fenoxaprop-P, fenpropidin, fenpyrazamine, fludioxonil, flufenacet, flumetralin, fosthiazate, lenacil, MCPA, MCPB, nicosulfuron, paraffin oils, paraffin oil, penconazole, picloram, prohexadione, propaquizafop, prosulfocarb, quizalofop-P-ethyl, quizalofop-P-tefuryl, sodium 5-nitroguaiacolate, sodium o-nitrophenolate, sodium p-nitrophenolate, sulphur, tebufenpyrad, tetraconazole, tri-allate, triflusulfuron and tritosulfuron (Text with EEA relevance)
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .
ANNEX The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows: (a) Part A is amended as follows: (1) in the sixth column, expiration of approval, of row 40, Deltamethrin, the date is replaced by ‘31 October 2023’; (2) in the sixth column, expiration of approval, of row 65, Flufenacet, the date is replaced by ‘31 October 2023’; (3) in the sixth column, expiration of approval, of row 69, Fosthiazate, the date is replaced by ‘31 October 2023’; (4) in the sixth column, expiration of approval, of row 102, Chlorotoluron, the date is replaced by ‘31 October 2023’; (5) in the sixth column, expiration of approval, of row 104, Daminozide, the date is replaced by ‘31 October 2023’; (6) in the sixth column, expiration of approval, of row 107, MCPA, the date is replaced by ‘31 October 2023’; (7) in the sixth column, expiration of approval, of row 108, MCPB, the date is replaced by ‘31 October 2023’; (8) in the sixth column, expiration of approval, of row 160, Prosulfocarb, the date is replaced by ‘31 October 2023’; (9) in the sixth column, expiration of approval, of row 161, Fludioxonil, the date is replaced by ‘31 October 2023’; (10) in the sixth column, expiration of approval, of row 162, Clomazone, the date is replaced by ‘31 October 2023’; (11) in the sixth column, expiration of approval, of row 169, Amidosulfuron, the date is replaced by ‘31 December 2023’; (12) in the sixth column, expiration of approval, of row 170, Nicosulfuron, the date is replaced by ‘31 December 2023’; (13) in the sixth column, expiration of approval, of row 171, Clofentezine, the date is replaced by ‘31 December 2023’; (14) in the sixth column, expiration of approval, of row 172, Dicamba, the date is replaced by ‘31 December 2023’; (15) in the sixth column, expiration of approval, of row 173, Difenoconazole, the date is replaced by ‘31 December 2023’; (16) in the sixth column, expiration of approval, of row 176, Lenacil, the date is replaced by ‘31 December 2023’; (17) in the sixth column, expiration of approval, of row 178, Picloram, the date is replaced by ‘31 December 2023’; (18) in the sixth column, expiration of approval, of row 180, Bifenox, the date is replaced by ‘31 December 2023’; (19) in the sixth column, expiration of approval, of row 181, Diflufenican, the date is replaced by ‘31 December 2023’; (20) in the sixth column, expiration of approval, of row 182, Fenoxaprop-P, the date is replaced by ‘31 December 2023’; (21) in the sixth column, expiration of approval, of row 183, Fenpropidin, the date is replaced by ‘31 December 2023’; (22) in the sixth column, expiration of approval, of row 186, Tritosulfuron, the date is replaced by ‘30 November 2023’; (23) in the sixth column, expiration of approval, of row 271, Bensulfuron, the date is replaced by ‘31 October 2023’; (24) in the sixth column, expiration of approval, of row 272, Sodium 5-nitroguaiacolate, the date is replaced by ‘31 October 2023’; (25) in the sixth column, expiration of approval, of row 273, Sodium o-nitrophenolate, the date is replaced by ‘31 October 2023’; (26) in the sixth column, expiration of approval, of row 274, Sodium p-nitrophenolate, the date is replaced by ‘31 October 2023’; (27) in the sixth column, expiration of approval, of row 275, Tebufenpyrad, the date is replaced by ‘31 October 2023’; (28) in the sixth column, expiration of approval, of row 276, Chlormequat, the date is replaced by ‘30 November 2023’; (29) in the sixth column, expiration of approval, of row 278, Propaquizafop, the date is replaced by ‘30 November 2023’; (30) in the sixth column, expiration of approval, of row 279, Quizalofop-P-ethyl and Quizalofop-P-tefuryl, the date is replaced by ‘30 November 2023’; (31) in the sixth column, expiration of approval, of row 284, Dimethachlor, the date is replaced by ‘31 December 2023’; (32) in the sixth column, expiration of approval, of row 285, Etofenprox, the date is replaced by ‘31 December 2023’; (33) in the sixth column, expiration of approval, of row 287, Penconazole, the date is replaced by ‘31 December 2023’; (34) in the sixth column, expiration of approval, of row 288, Tri-allate, the date is replaced by ‘31 December 2023’; (35) in the sixth column, expiration of approval, of row 289, Triflusulfuron, the date is replaced by ‘31 December 2023’; (36) in the sixth column, expiration of approval, of row 292, Sulphur, the date is replaced by ‘31 December 2023’; (37) in the sixth column, expiration of approval, of row 293, Tetraconazole, the date is replaced by ‘31 December 2023’; (38) in the sixth column, expiration of approval, of row 294, Paraffin oils, the date is replaced by ‘31 December 2023’; (39) in the sixth column, expiration of approval, of row 295, Paraffin oil, the date is replaced by ‘31 December 2023’; (40) in the sixth column, expiration of approval, of row 299, 2-phenylphenol (including its salts such as the sodium salt), the date is replaced by ‘31 December 2023’; (b) Part B is amended as follows: (1) in the sixth column, expiration of approval, of row 6, Prohexadione, the date is replaced by ‘31 December 2023’; (2) in the sixth column, expiration of approval, of row 18, 8-hydroxyquinoline, the date is replaced by ‘31 December 2023’; (3) in the sixth column, expiration of approval, of row 25, Fenpyrazamine, the date is replaced by ‘31 December 2023’; (c) Part E is amended as follows: (1) in the sixth column, expiration of approval, of row 1, Flumetralin, the date is replaced by ‘11 December 2023’; (2) in the sixth column, expiration of approval, of row 2, Esfenvalerate, the date is replaced by ‘31 December 2023’.
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.